|
Nov 9
|
The Weight-Loss Drug Showdown Is Coming. Why Eli Lilly’s Treatment Costs Less Than Wegovy.
|
|
Nov 9
|
AstraZeneca enters weight-loss market with oral GLP-1 drug
|
|
Nov 9
|
AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
|
|
Nov 9
|
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
|
|
Nov 9
|
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
|
|
Nov 9
|
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
|
|
Nov 9
|
Weight loss drugs transforming healthcare, may help with addiction -Reuters Events
|
|
Nov 9
|
Approval for Eli Lilly obesity drug sets up rival to Wegovy
|
|
Nov 8
|
FDA approves Eli Lilly's Mounjaro for weight loss
|
|
Nov 8
|
Eli Lilly Stock Jumps on Obesity Drug’s FDA Approval
|
|
Nov 8
|
Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic
|
|
Nov 8
|
Wegovy rival Zepbound wins approval amid weight-loss jab gold rush
|
|
Nov 8
|
Novo Nordisk to discontinue Levemir insulin in U.S. market
|
|
Nov 8
|
Data on Pfizer’s New Weight Loss Pill Is Coming. Why it’s Crucial for the Stock.
|
|
Nov 7
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
|
|
Nov 7
|
UPDATE 1-Novo Nordisk to present new data from weight-loss, diabetes trials
|
|
Nov 7
|
Should You Believe in the High Growth Potential of Novo Nordisk A/S (NVO)?
|
|
Nov 6
|
Why Novo Nordisk Stock Trounced the Market Today
|
|
Sep 13
|
Ozempic Maker Novo Rises After First Stock Split in a Decade
|
|
Sep 13
|
Novo Nordisk conducts a two-for-one stock split
|